跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ADC-1
首页
药物
ADC-1
ADC-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-CDCP1 ANTIBODY
US 2023050380 A1
申请人: CHIOME BIOSCIENCE INC
优先权: 2019
CN
EP
US
WO
11 件公开
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US 8435529 B2
申请人: GOVINDAN SERENGULAM V
优先权: 2010
US
8 件公开
ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS
EP 2968588 B1
申请人: ABBVIE DEUTSCHLAND
优先权: 2013
CN
EP
US
WO
7 件公开
Method for Construction of Nucleic Acid Self-Assembly-Mediated ADC Drug and Use Thereof
US 2024181076 A1
申请人: ASSEMBLY MEDICINE LLC
优先权: 2021
CN
EP
US
WO
5 件公开
ANTI-TFR1 ANTIBODY MAB11-22.1 CONJUGATES FOR CANCER TREATMENT
EP 4444752 A4
申请人: NORTHEAST PHARMACEUTICAL GROUP CO LTD
优先权: 2021
CN
EP
US
WO
5 件公开
LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF
EP 4659764 A1
申请人: LEPU BIOPHARMA CO LTD
优先权: 2023
CN
EP
WO
5 件公开
Disease therapy by inducing immune response to Trop-2 expressing cells
US 9382329 B2
申请人: IBC PHARMACEUTICALS INC
优先权: 2015
US
5 件公开
COMBINATION THERAPY WITH LIV1-ADC AND PD-1 ANTAGONIST
EP 4072583 A1
申请人: SEAGEN INC
优先权: 2019
CN
EP
US
WO
4 件公开
METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES
EP 4243877 A4
申请人: BIOATLA INC
优先权: 2020
CN
EP
US
WO
4 件公开
COMBINATION THERAPY FOR TREATING TUMOR ANTIGEN EXPRESSING CANCERS
EP 4508083 A1
申请人: GILEAD SCIENCES INC
优先权: 2022
CN
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈